体外膜氧合用于重症中东呼吸综合征冠状病毒感染
该研究回顾性收集2014年4月至2015年12月沙特阿拉伯5个ICU中难治性呼吸衰竭的MERS-CoV患者,比较ECMO组(17例)与常规治疗组(18例)的结局。两组基线特征相似;ECMO组住院死亡率更低(65% vs 100%,P=0.02),ICU住院时间更长(中位数25 vs 8天,P<0.01),住院时间无显著差异(中位数41 vs 31天,P=0.421)。ECMO组入住ICU第7天和第14天PaO2/FiO2更好(124 vs 63,138 vs 36,P<0.05),第1天和第14天去甲肾上腺素使用更少(29% vs 80%,36% vs 93%,P<0.05)。作者认为ECMO作为挽救治疗与难治性低氧血症MERS患者死亡率降低相关。
要点
- ECMO组住院死亡率65% vs 常规治疗组100%,P=0.02。
- ECMO组ICU住院时间中位数25天 vs 常规组8天,P<0.01;住院时间中位数41天 vs 31天,P=0.421,无显著差异。
- 入住ICU第7天PaO2/FiO2 ECMO组124 vs 常规组63,第14天138 vs 36,P<0.05。
- 入住ICU第1天去甲肾上腺素使用ECMO组29% vs 常规组80%,第14天36% vs 93%,P<0.05。
- 作者认为该研究为迄今最大样本,支持ECMO作为重症MERS-CoV患者的挽救治疗。
适用人群与场景
- 2014年4月至2015年12月沙特阿拉伯5个ICU中MERS-CoV合并难治性呼吸衰竭、常规策略失败的患者,共35例。
- ECMO组17例,常规治疗组18例;两组基线特征相似。
研究设计与关键结果
- 回顾性研究,纳入35例MERS-CoV难治性呼吸衰竭患者,ECMO组17例 vs 常规治疗组18例。
- 主要终点住院死亡率:ECMO组65% vs 常规组100%,P=0.02。
- 次要终点ICU住院时间:ECMO组中位数25天 vs 常规组8天,P<0.01;住院时间:ECMO组中位数41天 vs 常规组31天,P=0.421,无显著差异。
- 入住ICU第7天PaO2/FiO2:ECMO组124 vs 常规组63;第14天:ECMO组138 vs 常规组36,P<0.05。
- 入住ICU第1天去甲肾上腺素使用:ECMO组29% vs 常规组80%;第14天:ECMO组36% vs 常规组93%,P<0.05。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ECMO作为挽救治疗与难治性低氧血症MERS患者住院死亡率降低相关,支持在重症MERS-CoV患者中使用ECMO作为挽救治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Middle East respiratory syndrome (MERS) is caused by a coronavirus (MERS-CoV) and is characterized by hypoxemic respiratory failure. The objective of this study is to compare the outcomes of MERS-CoV patients before and after the availability of extracorporeal membrane oxygenation (ECMO) as a rescue therapy in severely hypoxemic patients who failed conventional strategies.
METHODS: We collected data retrospectively on MERS-CoV patients with refractory respiratory failure from April 2014 to December 2015 in 5 intensive care units (ICUs) in Saudi Arabia. Patients were classified into two groups: ECMO versus conventional therapy. Our primary outcome was in-hospital mortality; secondary outcomes included ICU and hospital length of stay.
RESULTS: Thirty-five patients were included; 17 received ECMO and 18 received conventional therapy. Both groups had similar baseline characteristics. The ECMO group had lower in-hospital mortality (65 vs. 100%, P = 0.02), longer ICU stay (median 25 vs. 8 days, respectively, P < 0.01), and similar hospital stay (median 41 vs. 31 days, P = 0.421). In addition, patients in the ECMO group had better PaO2/FiO2 at days 7 and 14 of admission to the ICU (124 vs. 63, and 138 vs. 36, P < 0.05), and less use of norepinephrine at days 1 and 14 (29 vs. 80%; and 36 vs. 93%, P < 0.05).
CONCLUSIONS: ECMO use, as a rescue therapy, was associated with lower mortality in MERS patients with refractory hypoxemia. The results of this, largest to date, support the use of ECMO as a rescue therapy in patients with severe MERS-CoV.
参考来源
- Alshahrani MS, Sindi A, Alshamsi F, et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care. 2018. PMID: 29330690. doi:10.1186/s13613-017-0350-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。